@article{oai:kanazawa-u.repo.nii.ac.jp:00043376,
 author = {小泉, 順二 and 稲津, 明広 and 梶波, 康二 and 馬渕, 宏 and Kitatani, Masako and Koizumi, Junji and Inazu, Akihiro and Kajinami, Kouji and Mabuchi, Hiroshi},
 issue = {1},
 journal = {Topics in Catalysis},
 month = {Jan},
 note = {A study was conducted to determine the clinical efficacy and tolerability of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase in seven patients with heterozygous familial hypercholesterolemia (FH) (defined as primary hypercholesterolemia with tendon xanthoma or primary hypercholesterolemia without tendon xanthomas and at least one first-degree relative with familial hypercholesterolemia). These patients were administrated 10 mg/d of simvastatin for up to 4 years. Simvastatin significantly reduced levels of both total cholesterol and low-density lipoprotein cholesterol during treatment; respective reduction rates were 28% and 34% after 1 month and 32% and 40% after 4 years. Serum high-density lipoprotein cholesterol levels slightly and insignificantly increased. Serum triglyseride levels fell significantly by 24% at month 6. After this study, all xanthomas had reduced in size. No adverse events related to simvastatin were observed. We conclude that long-term simvastatin therapy is clinically useful and well tolerated in patients with FH. Copyright © 1985 Published by Elsevier Inc., 金沢大学医薬保健研究域保健学系},
 pages = {62--71},
 title = {A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia},
 volume = {57},
 year = {1996}
}